Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiviral drug |
| gptkbp:administeredBy |
solution for injection
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:European_Medicines_Agency |
| gptkbp:ATCCode |
J05AX30
|
| gptkbp:brand |
gptkb:Hepcludex
|
| gptkbp:CASNumber |
1802002-60-3
|
| gptkbp:developedBy |
gptkb:MYR_GmbH
|
| gptkbp:drugClass |
antiviral
peptide inhibitor |
| gptkbp:hasMolecularFormula |
C91H130N22O22S
|
| https://www.w3.org/2000/01/rdf-schema#label |
bulevirtide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
entry inhibitor of hepatitis B and D viruses
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
fatigue
headache injection site reactions increased bile acids |
| gptkbp:target |
gptkb:NTCP_(sodium_taurocholate_co-transporting_polypeptide)
|
| gptkbp:UNII |
6Y7T3V58TI
|
| gptkbp:usedFor |
treatment of chronic hepatitis B
treatment of chronic hepatitis D |
| gptkbp:bfsParent |
gptkb:NTCP
|
| gptkbp:bfsLayer |
6
|